41 Hafta üzerindeki gebeliklerde antenatal serum belirteçlerinin değerlendirilmesi

CONCLUSION: There were no statistically significant differences in maternal serum markers for pregnant women having their period of ≥41 gestational week.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:OBJECTIVE: To examine association between maternal antenatal serum biomarkers and post-term pregnancies.

📊

Key Findings & Data:STUDY DESIGN: Singleton pregnant women (n=186) managed at the Zekai Tahir Burak Women’s Health, Education and Research Hospital in Turkey from July 2010 to December 2010 were analyzed retrospectively.

💡

Conclusion & Impact:CONCLUSION: There were no statistically significant differences in maternal serum markers for pregnant women having their period of ≥41 gestational week.

🔬Design:Research Article

📍Scope:2010 Verileri

⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: To examine association between maternal antenatal serum biomarkers and post-term pregnancies. STUDY DESIGN: Singleton pregnant women (n=186) managed at the Zekai Tahir Burak Women’s Health, Education and Research Hospital in Turkey from July 2010 to December 2010 were analyzed retrospectively. Maternal serum levels of PAPP-A, free β-hCG, AFP, HCG and unconjugated E3 were noted routinely in antenatal screening programs. We compared these biomarkers in pregnancies between 37 and 41 gestational weeks (n=73) and ≥41 (n=113) gestational weeks. RESULTS: There was no statistically significant difference in maternal PAPP-A, free beta-hCG, AFP, total hCG and unconjugated E3 levels between the two groups. Although birth weights were higher in pregnant women ≥41 weeks, this difference was not considered significant (p=0.19). There were no SGA babies in the group of post-term pregnancies. CONCLUSION: There were no statistically significant differences in maternal serum markers for pregnant women having their period of ≥41 gestational week.

Özet

AMAÇ: Postterm gebeliklerle maternal antenatal serum belirteçlerinin ilişkisini incelemektir. GEREÇ VE YÖNTEM: Temmuz 2010 - Aralık 2010 arasında Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Has tanesinde takip edilen 186 tekil gebeliği olan hasta retrospektif olarak çalışmaya dahil edildi. Antenatal tarama programında bakılan PAPP-A, free β-hCG, AFP, HCG ve E3 düzeyleri kaydedildi. Bu belirteçler 37-41.gebelik haftasında olan 73 hasta ile ≥ 41 hafta olan 113 hasta arasında karşılaştırıldı. BULGULAR: İki grup arasında PAPP-A, serbest beta-hCG, AFP, total hCG ve E3 düzeyleri açısından anlamlı farklılık saptanmadı. Her ne kadar doğum ağırlığı ≥ 41 hafta olan gebelerde daha fazla ise de istatistiksel anlamlılık saptanmadı (p=0,19). Postterm gebelik grubunda SGA bebek yoktu. SONUÇ: ≥41 gebelik haftasında olan hastalarda antenatal maternal serum belirteçlerinde anlamlı farklılık bulunmamaktadır

🔖

Cite This Article

KANSU, H. Ç., ENGİN, Y. Ü., TİMUR, H., YAMAN, S., YILMAZ, S., YAPAR, E. G. E., MOLAMAHMUTOĞLU, L. (2011). 41 Hafta üzerindeki gebeliklerde antenatal serum belirteçlerinin değerlendirilmesi. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 17 - Sayı: 2, 72–75. https://ajindex.com/articles/215418

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (11)

Spencer K, Souther V, Tul N. et al. performed a screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13:231-7
Cuckle, H. () Antenatal screening. Semin Neonatal 1998;3:1-8
Ong CYT, Liao AW, Spencer K. et al. First trimester maternal serum free beta human chorionic gonadotropin and pregnancy associated plasma protein A as a prediction of pregnancy complications. BJOG 2000;107:1265-70
Wenstrom KD, Owen J, Boots LR. et al. Elevated second trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 1994;171:1038-41
Westergaard JG, Sinosich MJ, Bugge M, Madsen LT, Teisner B, Gradzinskas JG. Pregnancy-associated plasma protein A in the prediction of early pregnancy failure. Am J Obstet Gynecol 1983;145:67-9 6. Speencer K, Cowans NJ, Avgıdou K, Molina F, Nicolaides KH. First trimester biochemical markers of aneuploidy and the prediction of small for gestational age fetuses. Ultrasound Obstet Gynecol 2008;31:15-19
Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, Johnson JA, Langlois S, Summers A, Wyatt P; Society of Obstetricians and Gynecologists of Canada Genetics Committee. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008;30:918-49
Mandruzzato G, Alfirevic Z, Chervenak F, Gruenebaum A, Heimstad R. Guidelines for the management of postterm pregnancy. J. Perinat. Med. 2010;38:111-19
Morris RK, Cnossen JS, Largejans M, Robson SC, Kleijnen J. Serum screening with Down’s syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-anaylsis. BMC Pregnancy and Childbirth 2008;8:33
Morrinsk LP, Kornman LH, Hallahan TW, Kloosterman MD, Beckhuis JR, De Wolf BT, Montigh A: Maternal serum levels of free beta hCG and PAP-A in the first trimestr of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 1998;18:147-52
Shipp TD, Wilkins H. The association of early-onset fetal growth restriction, elevated maternal serum alpha-fetoprotein, and the development of severe pre-eclampsia. Prenat Diag 1997;17:4:305-9
Xia YP, Zhu MW, Li XT, Zhou HP, Wang J, Lv JX, Zhong N. Chromosomal abnormalities and adverse pregnancy outcome with maternal serum second trimester t